Population of the Breakthrough Therapy Designation
Indication pursued in the pivotal trial as described by the company
“We are currently conducting a global, randomized, double-blind, Phase 2/3 FORTIFI-HN01 pivotal trial evaluating 1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus infection, or HPV, -negative head and neck squamous cell carcinoma, or HNSCC, whose tumors express programmed death-ligand 1 with combined positive score, or CPS, of ≥1.” (opens the source at this quote in a new tab)
HPV testing limited to oropharyngeal primary tumors
Pivotal trial primary sites, HPV status, PD-L1 threshold, and prior therapy
HPV-negative disease as the only population enrolled